Biotech IPOs may still be a bright spot, but the light has dimmed

Gen­Sight has been play­ing in one of the hottest sec­tors in biotech, de­vel­op­ing new gene ther­a­pies for rare eye dis­eases. But the French biotech nev­er could raise suf­fi­cient in­ter­est to com­plete an IPO in the U.S., so now it’s tak­ing its busi­ness plan, its pres­ti­gious sci­en­tif­ic ad­vis­ers and its deep-pock­et in­vestors and try­ing the game on the Paris ex­change, rolling out a much-re­duced ef­fort to bag $44 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.